/cloudfront-us-east-2.images.arcpublishing.com/reuters/3WRJIXZFNNJABBELXITXNDPKEM.jpg)
[ad_1]
A dose of CureVac vaccine or a placebo is seen in a study by German biotechnology company CureVac as part of a test for a new vaccine against coronavirus disease (COVID-19), in Brussels, Belgium , March 2, 2021. REUTERS / Yves Herman
FRANKFURT, Sept. 14 (Reuters) – German biotech company CureVac (5CV.DE) on Tuesday announced that it had canceled manufacturing contracts for its experimental COVID-19 vaccine with two potential partners, after rivals with approved injections increased the production.
Agreements with Swiss group Celonic and German Wacker (WCHG.DE) would be terminated, but existing production agreements with Rentschler Biopharma and Novartis (NOVN.S) would remain unchanged, CureVac said in a statement.
Manufacturing contracts with Bayer (BAYGn.DE) and Fareva were also not affected, a spokesperson added.
CureVac is far behind rivals BioNTech (22UAy.DE), partner of Pfizer (PFE.N) and Moderna (MRNA.O), in trying to develop a COVID-19 vaccine based on mRNA. The BioNTech-Pfizer alliance, in particular, has been a dominant force among suppliers in Western countries, with more than a billion doses delivered to date.
“The continued increase in mRNA manufacturing capacity as well as the progress of large-scale vaccination efforts have dramatically altered the demand for our first generation COVID-19 vaccine, CVnCoV, in recent months,” said CureVac Director of Operations, Malte Greune.
Financial terms of the cancellation will not be disclosed, the company added.
CureVac released disappointing test data on its initial vaccine candidate in June and July, and European regulatory approval is still pending. Read more
He is also working with GlaxoSmithKline (GSK.L) on a next generation of COVID-19 vaccines. Read more
Reporting by Ludwig Burger and Patricia Weiss; Editing by Maria Sheahan
Our Standards: The Thomson Reuters Trust Principles.
Source link
